The Bayer Of Bad News

Germany’s Bayer was the bearer of bad news for investors today, with shares experiencing their largest one-day decline in over three years. 📉

The pharma and biotech company aborted a large late-stage trial testing a new anti-clotting drug due to a lack of efficacy. While failures are common in this field, this was the company’s most promising development project. Its statement says that the experimental anticoagulant asundexian was shown to be inferior to Bristol-Myers Squibb and Pfizer’s established treatments. ❌

And if that wasn’t bad enough, regulators also ordered the company to pay $1.56 billion in the latest U.S. lawsuit over its commonly-used Roundup weedkiller. A Missouri jury ordered the payout to four plaintiffs who claimed the product caused injuries, including cancer. Ultimately, it found that Bayer’s Monsanto business was liable for claims of negligence, design defects, and failing to warn plaintiffs of the potential dangers of using Roundup.

As a result of the many setbacks, new Bayer CEO Bill Anderson is reportedly weighing options to break up the company. Splitting the business into three parts: prescription drugs, consumer health products, crop chemicals and seeds, along with cost-cutting, could help revive its share price. ✂️

$BAYRY shares fell over 17% to 17-year lows as investors assess the company’s future. 🙃

More in   Earnings

View All

Walmart Bets Big On Advertising

One of the core themes we’ve been discussing for a long time is the “ad-ification” of everything. No matter where you go or what you do, you’re likely being targeted by some form of advertising. And the reason why is because it’s such a high-margin, profitable business opportunity. 🎯

As a result, it’s no surprise to see America’s largest employer and big-box retailer, Walmart, leaning heavily into that narrative during its earnings call. 

Read It

CrowdStrike Bucks The Cyber Selloff

After Palo Alto Networks and other cybersecurity stocks failed to meet expectations, the market highly anticipated CrowdStrike’s earnings after the bell. And unlike its peers, the company delivered big time, so let’s take a look. 👇

Adjusted earnings per share of $0.95 beat expectations of $0.82, while revenues of $845 million topped the $839 million anticipated. Notably, the firm has reported GAAP net income for the past four quarters, and management expects that trend to continue. 💵

Read It

Speculation Heightens As Jumia Jumps

As we’ve discussed, speculation continues to spread to all corners of the market. Even those areas that have been left for dead for quite some time. Today’s example of this is Jumia Technologies, the “Amazon of Africa” that caught wildfire early in its life before the gravity of reality brought it back down to earth. 🛒

The company reported reducing its losses by over 90% in the fourth quarter as it focused on restoring order and gross merchandise value (GMV) growth. Like other struggling companies, it cut costs significantly and leveraged lower tax provisions to help drive the earnings improvement. 

Read It

Target Hits Its Mark With Membership Push

Once companies discovered that membership and loyalty programs drove additional customer visits and spending, there became apps for everything. Trust me, I’ve got the McDonald’s app on my phone because I get free fries or something with my occasional purchase… 📱

Nonetheless, this shit clearly works, and everyone wants a part of it. Given Target’s recent struggle, it’s not surprising that it’s jumping on the bandwagon as part of its turnaround strategy. 

Read It